Nuvation Bio Posts $62.9M 2025 Revenue, IBTROZI Drives Q4 Growth
Nuvation Bio reported Q4 2025 revenue of $41.9M and full-year revenue of $62.9M, driven by IBTROZI net U.S. product revenue of $15.7M in Q4 and $24.7M for 2025. By year-end, 432 patients started IBTROZI—216 in Q4—with launching at six times the pace of prior ROS1 TKIs.
1. Financial Performance
Nuvation Bio generated $41.9 million in Q4 2025 revenue and $62.9 million for full-year 2025, with IBTROZI net U.S. product revenue of $15.7 million in Q4 and $24.7 million for the year, underscoring strong commercial momentum.
2. IBTROZI Commercial Rollout
By year-end 2025, 432 patients initiated IBTROZI therapy, including 216 in the fourth quarter, achieving a launch pace approximately six times faster than prior ROS1 TKIs across 47 sales territories. The company reported 75% of 2025 discontinuations in later-line patients and anticipates improved retention as use shifts upstream, supported by broad formulary coverage and its NuvationConnect patient support program.
3. Pipeline Progress
Nuvation raised enrollment for the global pivotal Phase III SIGMA trial of safusidenib in IDH1-mutant glioma, targeting 300 patients with an expected 2029 readout, and launched a separate 40-patient cohort in grade 3 oligodendroglioma slated for 2027 readout, positioning the program for potential accelerated approval based on response rates.